Clinical development decisions are often evaluated through the lens of regulatory success. Yet many of the most costly challenges in late-stage development and post-approval performance originate much earlier: in trial design choices, assumptions about the market, and the questions that are (or are not) asked at the beginning. This article explores why early-stage decisions shape downstream outcomes more than is often recognized, and why misalignment between clinical, patient, and market perspectives frequently emerges long before a product reaches approval.
After supporting clinical development programs across multiple therapeutic areas, I have observed the same pattern repeatedly: the most expensive problems are often created long before they are discovered. The issue is rarely a lack of effort or expertise. More often, key assumptions remain unchallenged, important questions are asked too late, or decisions are made without a full understanding of how the market actually works.
Recruitment problems are often strategic problems
Patient recruitment remains one of the most discussed challenges in clinical development. Yet recruitment difficulties are frequently treated as operational issues.
Organizations often point to sites, CROs, investigators, or patient availability as the root cause of enrollment delays. Sometimes that is true. Often it is not.
Many recruitment challenges can be traced back to earlier decisions:
- Eligibility criteria may not reflect real-world clinical practice
- Referral pathways may not be fully understood
- The target patient population may be smaller or less accessible than expected
- Key physicians may face practical barriers to identifying and referring eligible patients
By the time recruitment begins, the problem already exists. Execution simply reveals it.
This is why successful recruitment strategies often start long before the first site is activated. They begin with a realistic understanding of how patients move through the healthcare system and how treatment decisions are actually made.
The costliest questions are the ones asked too late
Not all unanswered questions carry the same risk. Some become expensive simply because they remain unanswered for too long:
- Which endpoints matter most to physicians?
- What outcomes are meaningful to patients in everyday practice?
- What evidence will payers require to support reimbursement decisions?
- Which patient segments create the greatest long-term value?
- What factors will ultimately drive physician adoption?
The later these questions are addressed, the fewer options remain available. Development decisions accumulate, flexibility decreases, and generating missing evidence becomes increasingly difficult and costly.
In clinical development, timing matters as much as the answer itself. The best questions are often not the ones that solve today’s problem. They are the ones that prevent tomorrow’s problems.
Approval is not the same as adoption
Generating clinical evidence is essential. However, not all evidence serves the same purpose. Some evidence helps achieve regulatory approval. Other evidence supports reimbursement, physician confidence, treatment adoption, and differentiation in an increasingly competitive market. The distinction matters.
A product can achieve its primary clinical objectives, obtain approval, and still face challenges gaining traction in routine practice.
This often happens when development programs focus primarily on regulatory requirements while underestimating the questions that physicians, patients, and payers will ask later.
Clinical development and commercial success are closely connected. Decisions made during trial design frequently influence market outcomes years later. The organizations that recognize this early are often better positioned to translate clinical success into commercial success.
The hidden cost of internal assumptions
Perhaps the most underestimated risk in clinical development is the assumption that the market behaves the way internal teams expect it to.
Every organization develops views on patients, clinicians, competitors, and payers. These assumptions help teams move forward, but they can also create blind spots:
- Patients do not always prioritize what development teams believe they prioritize
- Physicians do not always make decisions for the reasons companies expect
- Payers often evaluate value through a different lens than internal stakeholders anticipate
- Competitors frequently influence the market in ways that are not immediately visible
The challenge is not that assumptions exist. Every organization has them. The challenge is failing to test them early enough.
Information is rarely the problem
Clinical development teams have never had access to more information than they do today. Scientific publications, conference presentations, competitor intelligence, physician feedback, patient insights, real-world evidence, and increasingly advanced analytical tools provide a constant flow of data.
Yet information is rarely the limiting factor. The real challenge is determining which questions matter most, which assumptions require validation, and which uncertainties are significant enough to influence development decisions.
Wrapping up
In my experience, successful programs do not necessarily generate more information than others. They develop a clearer understanding of what is driving outcomes and focus their efforts on the decisions that matter most.
Because the objective is not to eliminate uncertainty. The objective is to identify the uncertainties that matter while there is still time to act on them. And in many cases, that determines success long before the first patient is recruited.